Dexmedetomidine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
ICU Sedation
Conditions
ICU Sedation
Trial Timeline
Mar 21, 2017 → May 21, 2018
NCT ID
NCT03813277About Dexmedetomidine
Dexmedetomidine is a approved stage product being developed by Orion Corporation for ICU Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT03813277. Target conditions include ICU Sedation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813277 | Approved | Completed |
| NCT02252523 | Phase 2 | UNKNOWN |
| NCT01266252 | Phase 3 | Completed |
| NCT00747721 | Phase 1 | Completed |
| NCT00226785 | Phase 3 | Terminated |
Competing Products
20 competing products in ICU Sedation